These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 15902297

  • 1. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
    Trus MR, Yang L, Suarez Saiz F, Bordeleau L, Jurisica I, Minden MD.
    Leukemia; 2005 Jul; 19(7):1161-8. PubMed ID: 15902297
    [Abstract] [Full Text] [Related]

  • 2. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
    Qi H, Ratnam M.
    Cancer Res; 2006 Jun 01; 66(11):5875-82. PubMed ID: 16740727
    [Abstract] [Full Text] [Related]

  • 3. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells.
    Wu Y, Guo SW.
    Eur J Obstet Gynecol Reprod Biol; 2008 Apr 01; 137(2):198-203. PubMed ID: 17376583
    [Abstract] [Full Text] [Related]

  • 4. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N.
    Ann Hematol; 2005 Dec 01; 84 Suppl 1():61-6. PubMed ID: 16270213
    [Abstract] [Full Text] [Related]

  • 5. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals.
    Hu ZB, Yang GS, Li M, Miyamoto N, Minden MD, McCulloch EA.
    Leukemia; 1995 May 01; 9(5):789-98. PubMed ID: 7769841
    [Abstract] [Full Text] [Related]

  • 6. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
    Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG.
    Cancer; 2005 Dec 15; 104(12):2717-25. PubMed ID: 16294345
    [Abstract] [Full Text] [Related]

  • 7. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
    Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N.
    Cancer; 2006 Jan 01; 106(1):112-9. PubMed ID: 16323176
    [Abstract] [Full Text] [Related]

  • 8. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
    Rocchi P, Tonelli R, Camerin C, Purgato S, Fronza R, Bianucci F, Guerra F, Pession A, Ferreri AM.
    Oncol Rep; 2005 Jun 01; 13(6):1139-44. PubMed ID: 15870934
    [Abstract] [Full Text] [Related]

  • 9. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R, Carducci MA.
    Prostate; 2007 Jul 01; 67(10):1099-110. PubMed ID: 17477369
    [Abstract] [Full Text] [Related]

  • 10. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
    Raffoux E, Chaibi P, Dombret H, Degos L.
    Haematologica; 2005 Jul 01; 90(7):986-8. PubMed ID: 15996941
    [Abstract] [Full Text] [Related]

  • 11. Valproic acid for the treatment of myeloid malignancies.
    Kuendgen A, Gattermann N.
    Cancer; 2007 Sep 01; 110(5):943-54. PubMed ID: 17647267
    [Abstract] [Full Text] [Related]

  • 12. Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.
    Wang AH, Wei L, Chen L, Zhao SQ, Wu WL, Shen ZX, Li JM.
    Ann Hematol; 2011 Aug 01; 90(8):917-31. PubMed ID: 21340723
    [Abstract] [Full Text] [Related]

  • 13. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
    Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F, Fiorini R, Spiriti MA, Petti MC, Venditti A, Amadori S, Mandelli F, Pelicci PG, Nervi C.
    Cancer Res; 2006 Sep 01; 66(17):8903-11. PubMed ID: 16951208
    [Abstract] [Full Text] [Related]

  • 14. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A, Dedes KJ, Imesch P, Von Bueren AO, Fink D.
    Int J Oncol; 2007 Sep 01; 31(3):633-41. PubMed ID: 17671692
    [Abstract] [Full Text] [Related]

  • 15. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.
    Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR.
    Leukemia; 2009 Apr 01; 23(4):641-8. PubMed ID: 19151770
    [Abstract] [Full Text] [Related]

  • 16. Epigallocatechin-3-gallate induces cell death in acute myeloid leukaemia cells and supports all-trans retinoic acid-induced neutrophil differentiation via death-associated protein kinase 2.
    Britschgi A, Simon HU, Tobler A, Fey MF, Tschan MP.
    Br J Haematol; 2010 Apr 01; 149(1):55-64. PubMed ID: 20096012
    [Abstract] [Full Text] [Related]

  • 17. Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.
    Noack K, Mahendrarajah N, Hennig D, Schmidt L, Grebien F, Hildebrand D, Christmann M, Kaina B, Sellmer A, Mahboobi S, Kubatzky K, Heinzel T, Krämer OH.
    Arch Toxicol; 2017 May 01; 91(5):2191-2208. PubMed ID: 27807597
    [Abstract] [Full Text] [Related]

  • 18. Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells.
    Siitonen T, Koistinen P, Savolainen ER.
    Leuk Res; 2005 Nov 01; 29(11):1335-42. PubMed ID: 15936818
    [Abstract] [Full Text] [Related]

  • 19. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
    Fredly H, Reikvam H, Gjertsen BT, Bruserud O.
    Am J Hematol; 2012 Apr 01; 87(4):368-76. PubMed ID: 22374841
    [Abstract] [Full Text] [Related]

  • 20. Elevated FOSB-expression; a potential marker of valproate sensitivity in AML.
    Khanim FL, Bradbury CA, Arrazi J, Hayden RE, Rye A, Basu S, MacWhannell A, Sawers A, Griffiths M, Cook M, Freeman S, Nightingale KP, Grimwade D, Falciani F, Turner BM, Bunce CM, Craddock C.
    Br J Haematol; 2009 Feb 01; 144(3):332-41. PubMed ID: 19036090
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.